Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced today that Presbia will be
participating at the 20THEuropean Society of Cataract &
Refractive Surgeons (ESCRS) Winter Meeting. The ESCRS is Europe's
leading organization for cataract and refractive surgeons and is at the
forefront of development in anterior segment surgery. The event will be
held the 26th through 28th of February at Megaron
Congress Centre in Athens, Greece.
Vladimir Feingold, Presbia's Chief Technology Officer and a Presbia
board member, will present a Poster at the Meeting featuring an analysis
of 275 patients having undergone the implantation of the Presbia
Flexivue Microlens™ and an evaluation of their significant improvement
in near-vision. The multicenter study was conducted in Japan, Greece,
Ireland, Czech Republic and Italy.
"While we have approvals to commercialize the Presbia Flexivue
Microlens™ in dozens of countries worldwide, we're taking a
highly-focused approach to create awareness of our surgical solution for
near-vision loss. We continue to lay the groundwork for
commercialization in Europe, predominately Germany, our next targeted
area, and are underway in Asia-Pacific with an increasing presence in
South Korea," said Todd Cooper, President and CEO of Presbia. "The
gathering of key industry leaders at the ESCRS winter meeting will
further the awareness of our Microlens implant as a groundbreaking
treatment for near-vision restoration for patients, eliminating the need
for reading glasses."
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160222005270/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media